Advertisement

Topics

Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms

04:48 EDT 19 Oct 2016 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
NEW YORK, Oct. 19, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Patent and Trademark Office has ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms"

Quick Search
Advertisement
 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...